WO2010109612A1 - 医薬組成物容器 - Google Patents

医薬組成物容器 Download PDF

Info

Publication number
WO2010109612A1
WO2010109612A1 PCT/JP2009/055974 JP2009055974W WO2010109612A1 WO 2010109612 A1 WO2010109612 A1 WO 2010109612A1 JP 2009055974 W JP2009055974 W JP 2009055974W WO 2010109612 A1 WO2010109612 A1 WO 2010109612A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
chamber
container
weak seal
auxiliary substance
Prior art date
Application number
PCT/JP2009/055974
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
修司 盛本
Original Assignee
株式会社モリモト医薬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社モリモト医薬 filed Critical 株式会社モリモト医薬
Priority to PCT/JP2009/055974 priority Critical patent/WO2010109612A1/ja
Priority to CN2010800119699A priority patent/CN102438574A/zh
Priority to US13/257,426 priority patent/US20120006704A1/en
Priority to JP2011506112A priority patent/JP5588967B2/ja
Priority to EP10756164.9A priority patent/EP2412358A4/en
Priority to KR1020117024736A priority patent/KR101723197B1/ko
Priority to PCT/JP2010/055214 priority patent/WO2010110368A1/ja
Publication of WO2010109612A1 publication Critical patent/WO2010109612A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2024—Separating means having peelable seals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3261—Flexible containers having several compartments
    • B65D81/3266—Flexible containers having several compartments separated by a common rupturable seal, a clip or other removable fastening device

Definitions

  • the present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container capable of enhancing cleanliness when swallowing the pharmaceutical composition.
  • Patent Document 1 discloses a multi-chamber container.
  • This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state.
  • the other space contains a dense fluid substance in a sealed state.
  • Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.
  • Patent Document 1 there is a problem that when taking a granular agent, there is a very high possibility that bacteria or other adverse effects on the patient enter the patient's body.
  • the technical problem of the present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a pharmaceutical composition container that can enhance cleanliness when swallowing the pharmaceutical composition. It is in.
  • the pharmaceutical composition container 10 includes at least three spaces 30, 32, 34, 36, and 38 in the container body 20.
  • the pharmaceutical composition container 10 further includes a cover 22. Between two adjacent spaces 140, 142, 144, and 146 are closed.
  • the space 140, 142, 144, 146 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10.
  • At least one of the spaces is an open space 38 having an opening 60.
  • a swallowing aid substance 40 is accommodated in a swallowing aid substance chamber 30 which is at least one of the spaces.
  • the pharmaceutical compositions 80 and 82 are accommodated in the pharmaceutical composition chambers 34 and 36 which are at least one of the spaces.
  • a portion of the container body 20 that forms the open space 38 is covered by the cover 22.
  • the part which forms the space 38 with an opening among the container main bodies 20 is covered with the cover 22 before the part is applied to a person's mouth. Thereby, the cleanliness of the part is kept high. As a result, cleanliness when swallowing the pharmaceutical composition can be improved.
  • the cover 22 described above is integral with the container body 20.
  • the at least three spaces 30, 32, 34, 36, 38 and the cover 22 described above are arranged so as to form one row.
  • a space 38 with openings is arranged at one end of the row.
  • a cover 22 is disposed at the other end of the row. The container body 20 and the cover 22 can be bent, and the container body 20 and the cover 22 are bent, so that the opening 60 and the cover 22 are opposed to each other.
  • the inclusions 42 and 44 are accommodated in the pharmaceutical composition chambers 34 and 36 described above. In this case, at least the surface of the inclusions 42 and 44 is dissolved with respect to the component of the swallowing auxiliary substance 40.
  • the inclusions 42 and 44 contain pharmaceutical compositions 80 and 82.
  • the swallowing auxiliary substance 40 When the swallowing auxiliary substance 40 is guided to the pharmaceutical composition chambers 34 and 36, at least the surface of the inclusions 42 and 44 is dissolved with respect to the components of the swallowing auxiliary substance 40. Accordingly, when the opening 60 is placed on the mouth of a person who has difficulty in swallowing and the swallowing auxiliary substance 40 and the inclusions 42 and 44 are pushed out from the opening 60, the person who has difficulty in swallowing while being wrapped in the swallowing auxiliary substance 40 The contents 42 and 44 are placed in the mouth. At this time, the surfaces of the inclusions 42 and 44 are melted. Since the surface is melted after being wrapped in the swallowing auxiliary substance 40, even if it is difficult for swallowing, the contents 42 and 44 can be swallowed easily.
  • the pharmaceutical compositions 80 and 82 are also swallowed. However, the pharmaceutical compositions 80 and 82 in the inclusions 42 and 44 are not scattered until the inclusions 42 and 44 are sufficiently melted. Furthermore, the residual amount of the pharmaceutical compositions 80 and 82 in the pharmaceutical composition chambers 34 and 36 can be reduced by wrapping the pharmaceutical compositions 80 and 82 with the inclusions 42 and 44.
  • the cleanliness when swallowing the pharmaceutical composition can be enhanced.
  • the configuration of the pharmaceutical composition container 10 according to this embodiment will be described with reference to FIG.
  • the pharmaceutical composition container 10 according to the present embodiment includes a container body 20 and a cover 22 integrated with the container body 20.
  • the container body 20 and the cover 22 according to the present embodiment are formed by bonding two laminated materials 50 together.
  • the laminated material 50 will be described later.
  • the container body 20 includes a swallowing auxiliary substance chamber 30, an intermediate chamber 32, a first pharmaceutical composition chamber 34, a second pharmaceutical composition chamber 36, and a space 38 with an opening.
  • the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 are formed so as to maintain airtightness with respect to the external space around the pharmaceutical composition container 10. Yes.
  • FIG. 2 is a cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment.
  • the cover 22 can cover the outside of the portion of the container body 20 that forms the open space 38. This is possible because the laminated material 50 according to the present embodiment can be bent.
  • a swallowing auxiliary substance 40 is accommodated.
  • the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water.
  • the moisture content of the jelly is set so as to satisfy the following requirements. The requirement is that at least the time from when the swallowing auxiliary substance 40 covers the surfaces of the first and second inclusions 42 and 44, which will be described later, until the first and second inclusions 42 and 44 are completely dissolved. This is a requirement that 2 minutes can be secured.
  • a first storage 42 is accommodated.
  • a granular medicine or other first pharmaceutical composition 80 is contained in the first inclusion 42.
  • the material of the first inclusion 42 according to this embodiment is a starch wafer having a thickness of 15 ⁇ m.
  • the second inclusion 44 is accommodated in the second pharmaceutical composition chamber 36.
  • a second pharmaceutical composition 82 is stored in the second storage 44.
  • the second pharmaceutical composition 82 is a substance different in kind from the granular first pharmaceutical composition 80.
  • the material of the second inclusion 44 according to this embodiment is a starch wafer having a thickness of 10 ⁇ m.
  • the opening of the 1st thing 42 and the 2nd thing 44 is sealed by twisting the part which corresponds to the inlet_port
  • the reason why the oblate is used as the material of the first and second inclusions 42 and 44 is that the functions described below are required for the first and second inclusions 42 and 44.
  • the function is a function that when the swallowing auxiliary substance 40 covers the surface of the first inclusion 42 or the second inclusion 44, the surfaces start to melt, and after they are swallowed, they completely dissolve.
  • the oblate used for the first inclusion 42 is thicker than the oblate used for the second inclusion 44, so that the time from the start of covering by the swallowing auxiliary substance 40 until it completely melts is longer than that of the second inclusion 44. This is necessary. This is necessary because the first inclusion 42 is covered with the swallowing auxiliary substance 40 earlier than the second inclusion 44.
  • the reason why the 10 ⁇ m thick wafer is used as the material of the second inclusion 44 is to secure at least 2 minutes from when it is covered with the swallowing aid 40 until it completely melts. Of course, the thickness of the wafer should be appropriately selected according to the material.
  • the swallowing auxiliary substance chamber 30, the first pharmaceutical composition room 34, and the second pharmaceutical composition room 36 do not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, and the swallowing auxiliary substance 40.
  • Gas for example, nitrogen gas is sealed as necessary.
  • the intermediate chamber 32 and the open space 38 in the present embodiment are vacant until the first weak seal 140 or the fourth weak seal 146 described later is peeled off.
  • An empty room is a space in which nothing is accommodated or a gas that does not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, or the swallowing auxiliary substance 40 is accommodated.
  • the open space 38 has an opening 60. The opening 60 allows the outside of the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, the second pharmaceutical composition chamber 36, and the open space 38 to communicate with the inside thereof.
  • the opening 60 has the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36. Among these, the inside of what communicates with the space 38 with an opening is communicated with the outside of those spaces.
  • the swallowing auxiliary substance chamber 30 and the intermediate chamber 32 are partitioned by a first weak seal 140.
  • the intermediate chamber 32 and the first pharmaceutical composition chamber 34 are partitioned by a second weak seal 142.
  • the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are partitioned by a third weak seal 144.
  • a space between the second pharmaceutical composition chamber 36 and the open space 38 is partitioned by a fourth weak seal 146.
  • the first weak seal 140, the second weak seal 142, the third weak seal 144, and the fourth weak seal 146 (these are collectively referred to as “first weak seal 140 to fourth weak seal 146”) are the container body 20. It is arrange
  • the strength of the first weak seal 140 to the fourth weak seal 146 is lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162.
  • the bottom strong seal 160 is a portion where the surfaces of the laminated material 50 are bonded to each other at the boundary between the container body 20 and the cover 22.
  • the side strong seal 162 is a portion excluding the first weak seal 140 to the fourth weak seal 146 and the bottom strong seal 160 in the portion where the surfaces of the laminated material 50 are bonded to each other.
  • the strength of the first weak seal 140 to the fourth weak seal 146 is the pressure of the swallowing auxiliary substance 40 (this pressure is due to the fact that an adult applied force from outside the swallowing auxiliary substance chamber 30).
  • the specific method for breaking the space between the second pharmaceutical composition chamber 36 and the open space 38 is not limited to the method of breaking by the pressure of the swallowing auxiliary substance 40.
  • the first weak seal 140 to the fourth weak seal 146 may be torn by pinching and pulling the two laminated materials 50 with both hands.
  • FIG. 3 is an enlarged cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment.
  • the configuration of the laminated material 50 and the configurations of the first weak seal 140 to the fourth weak seal 146 will be described with reference to FIGS. 1 and 3.
  • the laminated material 50 according to the present embodiment includes an outer skin material 100, an intermediate material 102, and a closing material 104 (Note that these three-layer structures of the laminated material 50 are not shown in FIG. 2 and are omitted. Have been).
  • the closing materials 104, 104 of the two laminated materials 50 are fused to each other. This fused portion is destroyed prior to the skin material 100 and the intermediate material 102 by the force applied from the outside of the pharmaceutical composition container 10.
  • the melting point of the closing member 104 is low. Therefore, when heat is applied to the laminated material 50 from the outside of the skin material 100, the closing material 104 is melted before the skin material 100 and the intermediate material 102 are melted. Since the closing material 104 is melted before the outer skin material 100 and the intermediate material 102 are melted, only the closing material 104 can be fused. This fused portion is the first weak seal 140 to the fourth weak seal 146. Only the fourth weak seal 146 is shown in FIG.
  • the material of the closing material 104 corresponding to the first weak seal 140 to the fourth weak seal 146 is different from the material of the closing material 104 corresponding to the bottom strong seal 160 and the side strong seal 162 (however, the material of the outer skin material 100 and The material of the intermediate member 102 is the same between the portion corresponding to the first weak seal 140 to the fourth weak seal 146 and the portion corresponding to the bottom strong seal 160 and the side strong seal 162). Since they are different, the strength of the first weak seal 140 to the fourth weak seal 146 can be made lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162.
  • the material of the outer skin material 100 is polyethylene terephthalate.
  • the material of the intermediate material 102 is nylon.
  • the material of the portion corresponding to the first weak seal 140 to the fourth weak seal 146 in the closing material 104 is polyethylene.
  • FIG. 4 is a diagram showing a manufacturing procedure of the pharmaceutical composition container 10 according to the present embodiment.
  • the manufacturing procedure of the pharmaceutical composition container 10 will be described with reference to FIG.
  • the first step is a step of superimposing the two laminated materials 50 and 50 and heating the portion corresponding to the side portion of the pharmaceutical composition container 10. Thereby, as shown in FIG. 4A, the side strong seal 162 is formed.
  • the second step is a step of heating the vicinity of the intermediate chamber 32 in the laminated material 50.
  • a first weak seal 140 and a second weak seal 142 are formed.
  • a 3rd step is a step which inserts the 1st inclusion 42 between the two laminated materials 50 and 50, as FIG.4 (C) shows.
  • the fourth step is a step of heating the vicinity of the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 in the laminated material 50.
  • sticker 144 is formed as FIG.4 (D) shows.
  • the fifth step is a step of inserting the second inclusion 44 between the two laminated materials 50 and 50 as shown in FIG. 4 (E).
  • the sixth step is a step of heating the area between the second pharmaceutical composition chamber 36 and the open space 38 in the laminated material 50. Thereby, as shown in FIG. 4F, a fourth weak seal 146 is formed.
  • the seventh step is a step of filling the swallowing auxiliary substance 40 between the two laminated materials 50.
  • the portion of the first weak seal 140 in the container body 20 is bent, and the swallowing auxiliary substance chamber 30 is directed upward.
  • a nozzle (not shown) is inserted into the swallowing auxiliary substance chamber 30 and the swallowing auxiliary substance 40 is filled.
  • the eighth step is a step of heating the boundary portion between the container body 20 and the cover 22.
  • the bottom strong seal 160 is formed as shown in FIG.
  • the ninth step as shown in FIG. 4 (H), after the boundary portion between the container body 20 and the cover 22 is bent, the portion of the container body 20 that forms the open space 38 is formed between the cover 22. It is a step to insert into.
  • the pharmaceutical composition container 10 completed through these steps is stored in a paper box (not shown) and distributed.
  • FIG. 5 is a diagram showing a method of using the pharmaceutical composition container 10 according to the present embodiment. The procedure for taking out the first pharmaceutical composition 80 and the second pharmaceutical composition 82 from the pharmaceutical composition container 10 and taking them will be described with reference to FIG.
  • a caregiver or the like pulls out the distal end portion of the container main body 20 from the cover 22 so that the pharmaceutical composition container 10 in the form shown in FIG. 4 (H) is shown in FIG. 1 or FIG. 4 (G).
  • a caregiver or the like pushes the swallowing auxiliary substance chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal 140 by the pressure from the inside of the swallowing auxiliary substance chamber 30.
  • the swallowing auxiliary substance 40 is pushed out to the intermediate chamber 32.
  • the pushed swallowing auxiliary substance 40 fills the intermediate chamber 32.
  • the second weak seal 142 is peeled off by the pressure of the swallowing auxiliary substance 40 inside the intermediate chamber 32.
  • the cover 22 is folded toward the container body 20.
  • the second weak seal 142 is peeled off, the swallowing auxiliary substance 40 is pushed out into the first pharmaceutical composition chamber 34.
  • the pushed swallowing aid substance 40 fills the first pharmaceutical composition chamber 34. From this time, the surface of the first inclusion 42 starts to melt by the swallowing auxiliary substance 40.
  • a caregiver or the like causes the patient 200 to hold the pharmaceutical composition container 10.
  • the patient 200 further folds the cover 22 folded toward the container body 20 toward the container body 20, and squeezes the container body 20 and the cover 22.
  • pressure is applied to the swallowing auxiliary substance 40.
  • the third weak seal 144 is peeled off.
  • the swallowing auxiliary substance 40 together with the first inclusion 42 is pushed out into the second pharmaceutical composition chamber 36.
  • the pushed swallowing auxiliary substance 40 fills the second pharmaceutical composition chamber 36. From this time, the surface of the second inclusion 44 also starts to melt by the swallowing auxiliary substance 40.
  • the patient 200 After the swallowing auxiliary substance 40 is pushed out into the second pharmaceutical composition chamber 36, the patient 200 further folds the container body 20 and the cover 22 in the direction from the swallowing auxiliary substance chamber 30 toward the second pharmaceutical composition chamber 36, And squeeze them further. Thereby, pressure is applied to the fluid substance 40. As a result of the pressure being applied to the fluid material 40, the fourth weak seal 146 peels off. When the fourth weak seal 146 is peeled off, the swallowing assisting substance 40, the first storage object 42, and the second storage object 44 are pushed out into the space 38 with the opening. They are swallowed through the open space 38 and the patient's 200 mouth.
  • the surfaces of the first and second items 42 and 44 are dissolved in the swallowing auxiliary substance 40, the surfaces of the first and second items 42 and 44 are easy to slip. Since the surface of the 1st thing 42 and the 2nd thing 44 becomes easy to slip, the 1st thing 42 and the 2nd thing 44 are swallowed smoothly.
  • the pharmaceutical composition container 10 has the following eight effects.
  • the first effect is that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be swallowed easily.
  • a 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 have a bitter taste.
  • the third effect is an effect that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be prevented from scattering in the mouth.
  • the fourth effect is that there is no need to worry about the stability of the first pharmaceutical composition 80 and the second pharmaceutical composition 82.
  • the fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing.
  • the sixth effect is an effect that cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved.
  • the seventh effect is that the first and second items 42 and 44 can be pushed out smoothly.
  • the eighth effect is that the residual amount of the pharmaceutical compositions 80 and 82 inside the pharmaceutical composition container 10 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). It is.
  • the first effect will be described in detail.
  • the first storage 42 and the second storage 44 enter the mouth of the patient 200 while being wrapped in the swallowing assistance substance 40. At this time, the surfaces of the first inclusion 42 and the second inclusion 44 are melted. Since the surface is melted while being wrapped in the swallowing aid 40, even the patient 200 who is difficult to swallow can easily swallow the first and second items 42 and 44. Since the first stored product 42 and the second stored product 44 contain the pharmaceutical composition 80, swallowing the first stored product 42 and the second stored product 44 allows the first stored pharmaceutical product 80 and the second stored pharmaceutical composition 44. The object 82 is also swallowed. Thereby, the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 can be swallowed easily.
  • the first collection 42 and the second collection 44 enter the mouth of the patient 200 while being wrapped in the swallowing auxiliary substance 40.
  • the first pharmaceutical composition 80 and the second pharmaceutical composition 82 which are the contents of the first collection 42 and the second collection 44 are the swallowing auxiliary substance 40, the first collection 42 and the second collection 44.
  • the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are double-wrapped by the swallowing auxiliary substance 40, the first inclusion 42 and the second inclusion 44. Thereby, possibility that the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 will scatter in the mouth of the patient 200 becomes low. As a result, scattering of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the mouth can be suppressed.
  • the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are chemical substances. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the pharmaceutical composition loses its action as a medicine. For this reason, in many cases, a plurality of pharmaceutical compositions cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check beforehand whether their effects are lost.
  • the pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. It is substantially the same to store a single pharmaceutical composition in each space and to store a plurality of pharmaceutical compositions separately. This is the reason why it is not necessary to worry about the stability of the pharmaceutical composition if the pharmaceutical composition container 10 according to the present embodiment is used. Since there is no need to worry about the stability of the pharmaceutical composition, there is no need to examine in advance whether the efficacy of a plurality of pharmaceutical compositions has been lost.
  • the fifth effect will be described. After sequentially inducing the swallowing auxiliary substance 40 into the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36, swallowing the swallowing auxiliary substance 40, the first inclusion 42 and the second inclusion 44, The activity of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 itself does not have much influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.
  • the sixth effect will be described.
  • a portion of the container body 20 that forms the open space 38 is covered with the cover 22.
  • the frequency with which bacteria etc. adhere to the part which forms the space 38 with an opening among the container main bodies 20 becomes low.
  • the frequency of attachment of bacteria or the like is lower.
  • the first weak seal 140 to the fourth weak seal 146 can be swallowed so that the swallowing auxiliary substance 40, the first inclusion 42, and the second inclusion 44 can be swallowed. Since it is not necessary to touch the portion of the container body 20 that touches the mouth with an instrument or hand, the possibility of attachment of bacteria or viruses can be reduced. As a result, cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved.
  • the seventh effect will be described.
  • the end portion of the first pharmaceutical composition chamber 34 on the second pharmaceutical composition chamber 36 side becomes narrower as it approaches the second pharmaceutical composition chamber 36, and the first encapsulating is contained in the first pharmaceutical composition chamber 34. Since the object 42 is accommodated, when the 1st inclusion 42 is pushed out by the swallowing assistance substance 40, it can implement smoothly.
  • the end of the second pharmaceutical composition chamber 36 on the side of the open space 38 is narrowed as it approaches the open space 38, and the second inclusion 44 is accommodated in the second pharmaceutical composition chamber 36. Therefore, the second inclusion 44 is also pushed out with the same smoothness.
  • the eighth effect will be described.
  • the first pharmaceutical composition 80 and the second pharmaceutical composition 82 therein are also pushed out at the same time.
  • the remaining amounts of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are set to the first and second inclusions 42 and 44, respectively.
  • the first and second items 42 and 44 according to this embodiment are sealed. Since it is sealed, the possibility that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 leak out of the first and second inclusions 42 and 44 is extremely low. Since the possibility is very low, the residual amount of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 inside the pharmaceutical composition container 10 is reduced (actually, the residual amount is made an amount close to zero). be able to.
  • FIG. 6 is a partially cutaway view of the pharmaceutical composition container 210 according to the present embodiment.
  • the configuration of the pharmaceutical composition container 210 according to this embodiment will be described with reference to FIG.
  • the pharmaceutical composition container 210 according to this embodiment includes a container body 220 and a cover 222.
  • the container body 220 is formed of a single laminated material 50 that is folded and has an outer peripheral portion bonded thereto.
  • the cover 222 is formed of the laminated material 50 like the container body 220.
  • the cover 222 is integrated with the container main body 220.
  • the hatching at the left end of the pharmaceutical composition container 210 indicates a cross section of the laminated material 50.
  • the container body 220 has a swallowing auxiliary substance chamber 230, a pharmaceutical composition chamber 232, and a space 234 with an opening.
  • the swallowing auxiliary substance chamber 230 and the pharmaceutical composition chamber 232 are formed so as to maintain airtightness with respect to the external space around the pharmaceutical composition container 210.
  • the swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance chamber 230.
  • the first composition 42 is accommodated in the pharmaceutical composition chamber 232.
  • a first pharmaceutical composition 80 is stored in the first stored product 42. Until the first weak seal 240 and the second weak seal 242 described later are peeled off, the open space 234 is an empty space.
  • a gas that does not affect the first pharmaceutical composition 80 and the swallowing auxiliary substance 40 is sealed as necessary.
  • the swallowing auxiliary substance chamber 230 and the pharmaceutical composition chamber 232 are partitioned by a first weak seal 240.
  • the pharmaceutical composition chamber 232 and the open space 234 are partitioned by a second weak seal 242.
  • the 1st weak seal 240 and the 2nd weak seal 242 will be arrange
  • the strength of the first weak seal 240 and the second weak seal 242 is lower than the strength of the bottom strong seal 260 and the strength of the side strong seal 262.
  • the bottom strong seal 260 is a portion where the surfaces of the laminated material 50 are bonded to each other at the boundary between the container main body 220 and the cover 222.
  • the side strong seal 262 is a portion excluding the first weak seal 240 and the second weak seal 242 and the bottom strong seal 260 in the portion where the surfaces of the laminated material 50 are bonded to each other.
  • the strength of the first weak seal 240 and the second weak seal 242 is a strength that can be broken by the pressure of the swallowing auxiliary substance 40, as in the first embodiment.
  • the specific method for destroying the first weak seal 240 and the second weak seal 242 is not limited to the method of destroying by the pressure of the swallowing auxiliary substance 40.
  • the configurations of the first weak seal 240 and the second weak seal 242 are the same as the configurations of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment.
  • the configurations of the bottom strong seal 260 and the side strong seal 262 are the same as those of the bottom strong seal 160 and the side strong seal 162 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.
  • the two corners of the portion corresponding to the tip of the open space 234 in the container body 220 are bent.
  • FIG. 6 in order to make it easy to grasp the configuration of the pharmaceutical composition container 210, only one of the corners is bent.
  • the reason why the two corners are bent is to make it easier to insert the portion corresponding to the tip of the opening-equipped space 234 into the cover 222 as in the first embodiment. Therefore, if there is no particular problem, only one of the two corners may be bent.
  • the manufacturing procedure and usage method of the pharmaceutical composition container 210 according to the present embodiment are the same as the manufacturing procedure and usage method of the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.
  • the pharmaceutical composition container 210 has the following six effects.
  • the first effect is that the first pharmaceutical composition 80 can be swallowed easily.
  • a 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 has a bitter taste.
  • the third effect is that the first pharmaceutical composition 80 can be prevented from scattering in the mouth.
  • the fourth effect is that various types of solids can be taken by persons who have difficulty in swallowing.
  • the fifth effect is an effect that cleanliness when taking the first pharmaceutical composition 80 can be enhanced. Since the reason for achieving these effects is the same as in the first embodiment, detailed description thereof will not be repeated here.
  • the sixth effect is an effect that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 210 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). .
  • FIG. 7 is a partially cutaway view of the pharmaceutical composition container 310 according to the present embodiment.
  • the configuration of the pharmaceutical composition container 310 according to this embodiment will be described with reference to FIG.
  • the pharmaceutical composition container 310 according to this embodiment includes a container main body 320 and a cover 322.
  • the container body 220 is formed by welding the outer edges of the two laminated materials 50.
  • the cover 222 is separated from the container body 220.
  • the sheet forming the cover 222 is formed of a known resin.
  • the container body 320 includes a bag storage chamber 330, a first pharmaceutical composition chamber 334, a second pharmaceutical composition chamber 336, and an open space 338.
  • the bag storage chamber 330, the first pharmaceutical composition chamber 334, and the second pharmaceutical composition chamber 336 are formed so as to be airtight with respect to the external space around the container body 320.
  • an auxiliary substance storage bag 340 is stored in the bag storage chamber 330.
  • the auxiliary substance storage bag 340 is fixed in the bag storage chamber 330 by an outer peripheral strong seal 462 described later.
  • the auxiliary substance storage bag 340 stores the swallowing auxiliary substance 40.
  • the strength of one end of the auxiliary substance storage bag 340 facing the first weak seal 440 described later has the same structure as that of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment. . This part can therefore be destroyed by the pressure of the swallowing aid 40.
  • the swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 340 and then sandwiched between the container main bodies 320. After that, the outer peripheral strong seal 462 is formed, so that the auxiliary substance storage bag 340 is bonded to the outer peripheral strong seal 462.
  • the first inclusion 42 is accommodated.
  • a first pharmaceutical composition 80 is stored in the first stored product 42.
  • the powder 344 is accommodated in the second pharmaceutical composition chamber 336. Until the first weak seal 440 to the third weak seal 444 are peeled off, the open space 338 in this embodiment is an empty room.
  • the bag storage chamber 330 and the first pharmaceutical composition chamber 334 are partitioned by a first weak seal 440.
  • the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 are partitioned by a second weak seal 442.
  • the second pharmaceutical composition chamber 336 and the open space 338 are partitioned by a third weak seal 444.
  • the first weak seal 440, the second weak seal 442, and the third weak seal 444 are the spaces formed by the container body 320. It is arranged in a portion between two adjacent ones.
  • the strength of the first weak seal 440 to the third weak seal 444 is lower than the strength of the outer peripheral strong seal 462.
  • the outer peripheral strong seal 462 is a portion where the edge of the container body 320 is bonded.
  • the strength of the first weak seal 440 to the third weak seal 444 is a strength that can be broken by the pressure of the swallowing auxiliary substance 40, as in the first embodiment and the second embodiment.
  • the specific method for breaking the first weak seal 440 to the third weak seal 444 is limited to a method of breaking by the pressure of the swallowing auxiliary substance 40. Not.
  • the configuration of the first weak seal 440 to the third weak seal 444 is the same as the configuration of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment.
  • the configuration of the outer peripheral strong seal 462 is the same as that of the side strong seal 162 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.
  • the manufacturing procedure of the pharmaceutical composition container 310 will be described.
  • the first step is a step in which two laminated materials 50 are overlapped and the outer edges thereof are heated. However, the portion where the auxiliary substance storage bag 340 is sandwiched is not heated.
  • the second step is a step of heating the vicinity of the first weak seal 440 in the laminated material 50. Thereby, the first weak seal 440 is formed.
  • the third step is a step of inserting the first inclusion 42 between the laminated materials 50.
  • the fourth step is a step of heating the area between the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 in the laminated material 50. As a result, the second weak seal 442 is formed.
  • the fifth step is a step of filling powder 344 between the laminated materials 50.
  • the sixth step is a step of heating the area between the second pharmaceutical composition chamber 336 and the open space 338 in the laminated material 50. Thereby, the third weak seal 444 is formed.
  • the seventh step is a step of inserting the auxiliary substance storage bag 340 between the laminated materials 50. At this time, first, a portion of the first weak seal 440 in the container body 320 is bent, and the bag storage chamber 330 is directed upward. When the bag storage chamber 330 faces upward, the opening of the bag storage chamber 330 is greatly opened, and the auxiliary substance storage bag 340 is inserted therein.
  • the eighth step is a step of heating a portion of the outer edge of the container body 320 where the auxiliary substance storage bag 340 is sandwiched.
  • the ninth step is a step of covering the cover 322 outside the portion of the container body 320 that forms the open space 338.
  • the pharmaceutical composition container 310 completed through these steps is stored in a paper box (not shown) and distributed.
  • the method of using the pharmaceutical composition container 310 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment except that the cover 322 is first removed from the portion of the container body 320 that forms the open space 338. It is the same as the usage method of. Therefore, detailed description thereof will not be repeated here.
  • the pharmaceutical composition container 310 has the following five effects.
  • the first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily.
  • a 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 has a bitter taste.
  • the third effect is that there is no need to worry about the stability of the drug.
  • a 4th effect is an effect that the cleanliness at the time of taking the 1st pharmaceutical composition 80 and powder 344 can be improved.
  • the fifth effect is that the residual amount of the pharmaceutical compositions 80 and 82 inside the pharmaceutical composition container 310 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). It is. Since the reason for achieving these effects is the same as in the first embodiment, detailed description thereof will not be repeated here.
  • FIG. 8 is a partially cutaway view of the pharmaceutical composition container 510 according to the present embodiment.
  • the configuration of the pharmaceutical composition container 510 according to this embodiment will be described with reference to FIG.
  • a pharmaceutical composition container 510 according to this embodiment includes a container body 520 and a cover 522 integrated with the container body 520. Similar to the second embodiment, the container main body 520 and the cover 522 according to the present embodiment are formed by folding one laminated material 50 in two and bonding the outer circumferences together. In FIG. 8, the hatching at the right end of the pharmaceutical composition container 510 indicates a cross section of the laminated material 50.
  • the container body 520 includes a swallowing auxiliary substance chamber 530, an intermediate chamber 532, a first pharmaceutical composition chamber 534, a second pharmaceutical composition chamber 536, and a space 538 with an opening.
  • the swallowing auxiliary substance chamber 530, the intermediate chamber 532, the first pharmaceutical composition chamber 534, and the second pharmaceutical composition chamber 536 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 510. Yes.
  • the cover 522 can cover the outside of the portion of the container body 520 that forms the open space 538.
  • the third pharmaceutical composition 84 is accommodated in the first pharmaceutical composition chamber 534.
  • the third pharmaceutical composition 84 is a powder medicine.
  • a fourth pharmaceutical composition 86 is accommodated in the second pharmaceutical composition chamber 536.
  • the fourth pharmaceutical composition 86 is a different type of powder from the third pharmaceutical composition 84.
  • granular medicines and other substances may be accommodated in the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536.
  • the swallowing auxiliary substance chamber 530 In the swallowing auxiliary substance chamber 530, the first pharmaceutical composition chamber 534, and the second pharmaceutical composition chamber 536, gas that does not affect the third pharmaceutical composition 84, the fourth pharmaceutical composition 86, and the fluid substance 40 is present. Enclosed as necessary.
  • the intermediate chamber 532 and the open space 538 are empty.
  • the open space 538 has an opening.
  • the swallowing auxiliary substance chamber 530 and the intermediate chamber 532 are partitioned by a first weak seal 640.
  • the intermediate chamber 532 and the first pharmaceutical composition chamber 534 are partitioned by a second weak seal 642.
  • the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 are partitioned by a third weak seal 644.
  • a space between the second pharmaceutical composition chamber 536 and the open space 538 is partitioned by a fourth weak seal 646.
  • the strength of the first weak seal 640 to the fourth weak seal 646 is lower than the strength of the bottom strong seal 660 and the strength of the side strong seal 662.
  • the strength of the first weak seal 640 to the fourth weak seal 646 is based on the pressure of the fluid substance 40 (this pressure is due to an adult applying force from the outside of the swallowing auxiliary substance chamber 30). ) Is a strength that can be destroyed.
  • the specific method for breaking the space between the second pharmaceutical composition chamber 536 and the open space 538 is not limited to the method of breaking by the pressure of the flowable substance 40.
  • the method of using the pharmaceutical composition container 510 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.
  • the pharmaceutical composition container 510 has the following four effects.
  • a 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily.
  • the second effect is that there is no need to worry about the stability of the drug.
  • the third effect is that the pharmaceutical composition container 510 according to the present embodiment is used to swallow the pharmaceutical composition by providing a step at a portion adjacent to the third weak seal 644 in the side strong seal 662. This is an effect of preventing the tip of the pharmaceutical composition container 510 from entering the mouth of the patient 200 too much.
  • a 4th effect is an effect that the cleanliness at the time of taking the 3rd pharmaceutical composition 84 and the 4th pharmaceutical composition 86 can be improved.
  • FIG. 9 is a partially cutaway view of the pharmaceutical composition container 710 according to the present embodiment.
  • a pharmaceutical composition container 710 according to this embodiment includes a container body 820 and a cover 822 integrated with the container body 820.
  • the pharmaceutical composition container 710 is formed by bonding two laminated materials 50 as in the first embodiment and the third embodiment.
  • the container body 820 includes a swallowing auxiliary substance chamber 830, a first pharmaceutical composition chamber 834, and a space 838 with an opening.
  • the swallowing auxiliary substance chamber 830 and the first pharmaceutical composition chamber 834 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 710.
  • the third pharmaceutical composition 84 is accommodated in the first pharmaceutical composition chamber 834.
  • the first pharmaceutical composition chamber 834 may contain a granular drug or other substance.
  • a gas that does not affect the third pharmaceutical composition 84 and the flowable substance 40 is sealed as necessary.
  • the open space 838 is an empty space until the first weak seal 840 and the second weak seal 842 are peeled off.
  • the space 838 with an opening has an opening.
  • the swallowing auxiliary substance chamber 830 and the first pharmaceutical composition chamber 834 are partitioned by a first weak seal 840.
  • the first pharmaceutical composition chamber 834 and the open space 838 are partitioned by a second weak seal 842.
  • the strength of the first weak seal 840 and the second weak seal 842 is lower than the strength of the bottom strong seal 860 and the strength of the side strong seal 862.
  • the method of using the pharmaceutical composition container 710 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.
  • the pharmaceutical composition container 710 has the following three effects.
  • a 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily.
  • the second effect is that there is no need to worry about the stability of the drug.
  • a 3rd effect is an effect that the cleanliness at the time of taking the 3rd pharmaceutical composition 84 can be improved.
  • the pharmaceutical composition containers 10, 210, 310, 510, and 710 described in the present embodiment are illustrated to embody the technical idea of the present invention. This does not limit the material of the container body 20, 220, 320 to the embodiment described above. This does not limit the shape of the container main body 20, 220, 320, 510, 710, the shape of each space, the shape of the opening, their dimensions, their structure, and their arrangement to the above-described embodiments. .
  • the pharmaceutical composition containers 10, 210 and 310 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.
  • the forms of the first inclusion 42 and the second inclusion 44 are not limited to those described above.
  • the outer shape may be a rectangle. Moreover, it replaces with the 1st thing 42 and the 2nd thing 44, and the well-known capsule may be accommodated.
  • the shape of the space of the container main body 20, 220, 320, 510, 710 is not particularly limited.
  • the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 shown in FIG. 1 have a hexagonal shape, which may be a triangle, a rectangle, a pentagon, a heptagon or more polygon. It may be circular or elliptical.
  • the number of spaces included in the container main bodies 20, 220, and 320 may be four or more.
  • the pharmaceutical composition container 210 according to the second embodiment, the pharmaceutical composition container 310 according to the third embodiment, and the pharmaceutical composition container 710 according to the fifth embodiment are similar to the intermediate chamber 32 according to the first embodiment. Vacancy may be provided. Furthermore, in the first embodiment, the intermediate chamber 32 is not an essential space.
  • the container body 20 according to the first embodiment and the container body 320 according to the third embodiment are not limited to those obtained by bonding two sheets together.
  • the container main body 220 according to the second embodiment is not limited to one in which the outer edges of one sheet are bonded together.
  • the container body 220 according to the second embodiment may be a laminate of two sheets.
  • the container main body 20 according to the first embodiment and the container main body 320 according to the third embodiment may be formed by folding one sheet in two and bonding the outer edges.
  • the pharmaceutical composition is a powder or a granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto.
  • the pharmaceutical composition may be a tablet, a capsule or a simple lump in addition to a powder or a granule.
  • the pharmaceutical composition may not be accommodated in the first pharmaceutical composition chamber 34 or the second pharmaceutical composition chamber 36 in the form of a inclusion. That is, the pharmaceutical composition does not have to be wrapped by wafers or other packaging materials.
  • molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical.
  • the product molded as a pharmaceutical composition may be a food that has been recognized to improve health.
  • the swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to the aqueous solution.
  • the swallowing assisting substance has fluidity that can be moved back and forth in the space of the container body in an environment where the pharmaceutical composition container is used.
  • a compounding agent may be accommodated in one pharmaceutical composition chamber as long as it is confirmed that the drug does not change while the drug is distributed or stored.
  • the compounding agent described here means a mixture.
  • the inclusion is made of various materials that have been conventionally used as an edible film material in addition to the above-described starch-oblate having a thickness of 15 ⁇ m.
  • materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.
  • the pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine.
  • the container for taking medicine can be suitably used for a medicine filled by the following system.
  • the system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, and connected to a pharmaceutical production line to perform automatic operation for a long time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PCT/JP2009/055974 2009-03-25 2009-03-25 医薬組成物容器 WO2010109612A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/JP2009/055974 WO2010109612A1 (ja) 2009-03-25 2009-03-25 医薬組成物容器
CN2010800119699A CN102438574A (zh) 2009-03-25 2010-03-25 医药组成物容器
US13/257,426 US20120006704A1 (en) 2009-03-25 2010-03-25 Pharmaceutical composition container
JP2011506112A JP5588967B2 (ja) 2009-03-25 2010-03-25 医薬組成物容器
EP10756164.9A EP2412358A4 (en) 2009-03-25 2010-03-25 CONTAINER FOR PHARMACEUTICAL COMPOSITION
KR1020117024736A KR101723197B1 (ko) 2009-03-25 2010-03-25 의약조성물 용기
PCT/JP2010/055214 WO2010110368A1 (ja) 2009-03-25 2010-03-25 医薬組成物容器

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/055974 WO2010109612A1 (ja) 2009-03-25 2009-03-25 医薬組成物容器

Publications (1)

Publication Number Publication Date
WO2010109612A1 true WO2010109612A1 (ja) 2010-09-30

Family

ID=42780321

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2009/055974 WO2010109612A1 (ja) 2009-03-25 2009-03-25 医薬組成物容器
PCT/JP2010/055214 WO2010110368A1 (ja) 2009-03-25 2010-03-25 医薬組成物容器

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/055214 WO2010110368A1 (ja) 2009-03-25 2010-03-25 医薬組成物容器

Country Status (5)

Country Link
US (1) US20120006704A1 (ko)
EP (1) EP2412358A4 (ko)
KR (1) KR101723197B1 (ko)
CN (1) CN102438574A (ko)
WO (2) WO2010109612A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5896897B2 (ja) * 2010-03-29 2016-03-30 株式会社モリモト医薬 経口摂取用の医薬組成物容器

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3478871A (en) * 1968-04-29 1969-11-18 Kleer Vu Ind Inc Burst package with fold seal
JPS59142963A (ja) * 1983-01-24 1984-08-16 シ−・ア−ル・バ−ド・インコ−ポレ−テツド 混合用パツケ−ジ
JPH0355063A (ja) * 1989-07-24 1991-03-08 Nissho Corp 血液バッグの血液出入り口用チューブを密封保護するプロテクター
JPH10234820A (ja) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd 濃厚流動物質を併用する粉粒状剤及びこれらの複室型容器
JPH10291538A (ja) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc 薬剤入り容器
JP2003230618A (ja) * 2002-02-12 2003-08-19 Nipro Corp 複室容器
US20070119862A1 (en) * 2005-11-29 2007-05-31 Backes Larry P Unit dose flexible container

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1611119A (en) * 1926-09-24 1926-12-14 Lipper Mfg Co Inc Textile-mounted camphor ball
US3070094A (en) * 1959-02-25 1962-12-25 Stanley J Sarnoff Medicament and diluent storing, mixing, and dispensing device
US4402402A (en) * 1981-10-14 1983-09-06 Pike Brian R Barrier seal multiple-compartment package
US4534509A (en) * 1982-09-28 1985-08-13 Firmenich Sa Multiple compartment plastic packing
IT8253314V0 (it) * 1983-11-04 1982-05-21 Farmigea Spa Minicontenitori monodose o plurido se di prodotti farmaceutici
GB8911878D0 (en) * 1989-05-24 1989-07-12 Allen Nicholas J Mixing device
US5462526A (en) * 1993-09-15 1995-10-31 Mcgaw, Inc. Flexible, sterile container and method of making and using same
AUPP313398A0 (en) * 1998-04-22 1998-05-14 Boston Research And Development Company Disposable fluid or particulate applicator
SE9902610D0 (sv) * 1999-07-07 1999-07-07 Astra Ab Förslutningsanordning vid medicinsk behållare
JP4679838B2 (ja) * 2004-06-02 2011-05-11 株式会社細川洋行 医療用薬液容器
JP4656302B2 (ja) * 2005-03-25 2011-03-23 藤森工業株式会社 複室容器
EP1905455B1 (en) * 2005-06-06 2013-07-24 Ajinomoto Co., Inc. Capsule coating composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3478871A (en) * 1968-04-29 1969-11-18 Kleer Vu Ind Inc Burst package with fold seal
JPS59142963A (ja) * 1983-01-24 1984-08-16 シ−・ア−ル・バ−ド・インコ−ポレ−テツド 混合用パツケ−ジ
JPH0355063A (ja) * 1989-07-24 1991-03-08 Nissho Corp 血液バッグの血液出入り口用チューブを密封保護するプロテクター
JPH10234820A (ja) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd 濃厚流動物質を併用する粉粒状剤及びこれらの複室型容器
JPH10291538A (ja) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc 薬剤入り容器
JP2003230618A (ja) * 2002-02-12 2003-08-19 Nipro Corp 複室容器
US20070119862A1 (en) * 2005-11-29 2007-05-31 Backes Larry P Unit dose flexible container

Also Published As

Publication number Publication date
EP2412358A1 (en) 2012-02-01
CN102438574A (zh) 2012-05-02
EP2412358A4 (en) 2014-10-29
US20120006704A1 (en) 2012-01-12
WO2010110368A1 (ja) 2010-09-30
KR20110131296A (ko) 2011-12-06
KR101723197B1 (ko) 2017-04-05

Similar Documents

Publication Publication Date Title
JP5896897B2 (ja) 経口摂取用の医薬組成物容器
EP2702976B1 (en) Container for administering medication
WO2010110366A1 (ja) 医薬組成物容器
WO2010010866A1 (ja) 服用物収容容器
WO2010109612A1 (ja) 医薬組成物容器
JP5588967B2 (ja) 医薬組成物容器
WO2010109611A1 (ja) 医薬組成物容器
JP5931280B2 (ja) 分包体、分包体の製造方法および分包体の製造装置
JP5792939B2 (ja) 医薬組成物容器
JP5781439B2 (ja) 経口投与用製剤
JP5473629B2 (ja) 嚥下用容器
JP3855708B2 (ja) 容器
JP3732243B2 (ja) パウチ
WO2011122639A1 (ja) 経口摂取用の医薬組成物容器
WO2014064840A1 (ja) 薬剤経口投与装置
JP5873483B2 (ja) 投薬用容器
WO2016035134A1 (ja) 嚥下用容器、嚥下用容器セット、嚥下用容器セットの製造方法、および嚥下用容器セットの製造装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842226

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842226

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP